Nkarta announces initial NKX019 data in myositis, systemic sclerosis
At 4 billion cells, 83% of myositis and 86% of systemic sclerosis patients responded, with no CRS, ICANS, IEC-HS or GvHD among 40 patients.
See the latest news and media coverage for Nkarta. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage biotechnology company developing therapies for autoimmune diseases
nkartatx.comLast updated
In short: Nkarta presented initial autoimmune trial data and reported FDA-agreed outpatient dosing changes
At 4 billion cells, 83% of myositis and 86% of systemic sclerosis patients responded, with no CRS, ICANS, IEC-HS or GvHD among 40 patients.
Net loss is $33.3 million, cash of $216.0 million funds operations into 2029, and initial NKX019 data will be presented at ACR Convergence 2026.
Net loss was $40.4 million, cash of $243.2 million funds operations into 2029, and enrollment continues in Ntrust-1 and Ntrust-2 with initial data expected in 2026.
Cash and investments totaled $266.7 million; R&D expenses were $25.0 million and G&A $5.9 million.
Nkarta will present initial clinical data for its natural killer cell therapy in two disorders, myositis and systemic sclerosis, during the American College of Rheumatology...
Nkarta ( (NKTX)) just unveiled an announcement. On November 6, 2026, Nkarta announced a November 9 webcast to review initial clinical data from its Ntrust...
Enrollment ongoing at 4 billion cell dose level (12 billion cells in 3-dose cycle) across all indications in Ntrust-1 and Ntrust-2 Regulatory agreement supports expansion...
Nkarta stock jumps after FDA backs protocol changes for ongoing NKX019 studies, enabling outpatient...
Track Nkarta and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Nkarta and other trending companies.